AstraZeneca stock

AZN · LSE · GBp

Compare AstraZeneca
13,802.00 GBpChange from previous close: −1.65%Absolute change: −232.00 GBp

Close · November 17, 2026

Price history

+2.27% over the period

1 year: from 13,592.00 GBp (November 17, 2025) to 13,900.00 GBp (November 17, 2026), +2.27%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 202613,900.00 GBp
October 30, 202613,960.00 GBp
September 30, 202612,280.00 GBp
August 28, 202611,970.00 GBp
July 31, 202612,632.00 GBp
June 30, 202614,100.00 GBp
May 29, 202613,802.00 GBp
April 30, 202613,948.00 GBp
March 31, 202614,690.00 GBp
February 27, 202615,542.00 GBp
January 30, 202613,600.00 GBp
December 31, 202513,790.00 GBp
November 28, 202513,974.00 GBp
November 17, 202513,592.00 GBp

At a glance

  • The company

    Discovers, develops, manufactures and commercializes prescription medicines in oncology, cardiovascular, renal, metabolism, respiratory and rare diseases

  • Latest results

    Quarter to September 30, 2026 · EPS $2.79 (estimate $2.59)

TickerLandia's take on AstraZeneca

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low9,892.00 GBp
52-wk high15,732.00 GBp

−12.27% from the 52-week high

Analysts · 24 analysts

Average target16,344.10 GBp+18.42% vs. price

Buy 19 · Hold 5 · Sell 0 · Buy

TickerLandia Fingerprint: AstraZeneca

Compared with similar companies: low earnings stability, low financial strength, and high risk.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

AstraZeneca is pricier than similar companies

AstraZeneca's P/E (trailing 12 months): 26.6, +24% against the median of a group of 10 similar companies (21.5).

Compared with 10 similar companies

AstraZeneca's metrics compared with similar companies
MetricAstraZenecaPosition in the groupBand
P/E (trailing 12 months)26.6High
Forward P/E16.5High
Operating margin25.8%Middle
ROE22.6%Middle
Debt/equity0.66Middle

Grey band: the middle half of the group; tick: the median; dot: AstraZeneca. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$16.21B

Latest quarter · Q3 2026

Net income

$3.12B

Latest quarter · Q3 2026

Quarterly net margin

19.2%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
£217.66B
P/E
26.6
EPS
527.00 GBp
Volume
2.29M
Daily trading
€398.22M
Dividend yield
1.73%
Last ex-dividend on August 6, 2026

How AstraZeneca is changing

All results
  • Revenue grew 17.2% a year on average over the last 5 years

  • Operating margin rose from 8.5% to 23.4%

  • Profits turn into cash: free cash flow equal to 132% of net income

Returns

AstraZeneca returns with dividends

£1,000 invested in AstraZeneca 5 years ago, on November 17, 2021, would be worth £1,797 today with dividends reinvested: +79.70% in total, +12.44% per year. On price alone it would be £1,618 (+61.82%).

PeriodAstraZenecaFTSE 100£1,000 becomes
1 month+12.10%+0.38%£1,121
6 months+1.25%+5.98%£1,012
Year to date+0.80%+8.80%£1,008
1 year+4.03%+11.68%£1,040
3 years+43.85%+43.99%£1,439
5 years+79.70%+48.20%£1,797
10 years+324.29%+59.02%£4,243

Over the last 6 months it has done better than 18% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment

The chart in detail

AstraZeneca: technical analysis

AstraZeneca shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 11.2% below its all-time closing high (15,542.00 GBp, February 27, 2026).

Trend
No clear trend
RSI (14 sessions)
61
Between 30 and 70
vs 200-session average
+2.70%

Support and resistance

Price areas where AstraZeneca has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance15,462.18 GBp+12.03%2 touches, last on April 10, 2026
  2. Resistance14,212.67 GBp+2.98%3 touches, last on November 5, 2026
  3. Resistance13,913.97 GBp+0.81%3 touches, last on June 8, 2026
  4. Last price13,802.00 GBp
  5. Support13,465.00 GBp−2.44%2 touches, last on March 23, 2026
  6. Support13,264.33 GBp−3.90%6 touches, last on July 29, 2026
  7. Support12,714.00 GBp−7.88%2 touches, last on September 29, 2026

Volatility and risk

Over the last year it has moved roughly in line with the FTSE 100.

Beta (1 year) vs FTSE 100
1.06
Volatility (60 sessions, annualised)
27.0%
Largest fall in the last year
−26.26%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

AstraZeneca: seasonality

Average monthly price change over 34 years

+0.1%Jan−0.6%Feb+2.7%Mar+2.2%Apr+0.7%May+1.9%Jun+1.2%Jul+0.8%Aug−0.0%Sep+1.6%Oct+0.8%Nov+0.6%Dec

Over the last 34 years, the strongest month for AstraZeneca has been March: +2.65% on average, positive in 19 years out of 33. The weakest has been February: −0.62% on average, positive in 13 years out of 33. November, the current month, has been positive in 16 years out of 33 (+0.76% on average).

Show chart data
MonthAverageMedianPositive years
January+0.06%−0.70%15 of 33
February−0.62%−1.14%13 of 33
March+2.65%+1.92%19 of 33
April+2.19%+2.32%21 of 33
May+0.75%+0.73%18 of 33
June+1.91%+0.90%18 of 34
July+1.21%+1.41%22 of 34
August+0.80%−0.46%16 of 34
September−0.03%+0.94%21 of 34
October+1.58%+1.54%19 of 34
November+0.76%−0.57%16 of 33
December+0.59%+0.47%18 of 33

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

AstraZeneca and its competitors

Prescription medicines are the core of the business, covering the discovery, development, manufacture and commercialization of drugs. The portfolio spans oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and treatments for rare diseases, with products such as Tagrisso, Enhertu, Farxiga, Fasenra and Beyfortus. Physicians in primary and specialty care are served through distributors and local representative offices in the United Kingdom, the United States, the rest of Europe, Asia, Africa and Australasia.

Headquarters
Cambridge, United Kingdom
Employees
96,100
Founded
1992
Chief executive
Pascal Claude Soriot
AstraZeneca and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
AstraZenecaAZN$287.12B25.8%26.6+1.25%
NovartisNOVN$305.16B34.0%32.6+14.23%
Roche HoldingROP$387.48B33.1%26.7+25.84%
Novo NordiskNOVO.B$184.87B50.8%11.2−7.92%
SanofiSAN$116.52B22.3%25.5+17.04%
GSKGSK$102.04B30.5%18.0+0.35%

Same industry or related industries, similar size. Compare AstraZeneca with its competitors · Full profile